4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Disarming the intravascular innate immune response to improve treatment modalities for chronic kidney disease (DIREKT)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2017,
"Chronic kidney disease is world wide a major cause of end-stage renal disease (ESRD). 800.000 patients in Europe and in the US, respectively, require long-term treatment initially with peritoneal dialysis, followed by hemodialysis and kidney transplantation. Each ESRD patient on hemodialysis costs ≈€40000 to €80000 per year, has extremely poor quality of life and an average life expectancy of onl ...
Voir le projet
12
Participants partenaires
TERMINÉ
TOPIC: Targeting Cytotoxic Protein Oligomers (TOPIC)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
"Parkinson's disease and Huntington's disease are highly debilitating diseases for which no disease modifying treatment is available. This EID proposal, called TOPIC (Targeting Cytotoxic Protein Oligomers), will train 2 ESRs to target the oligomeric protein aggregate which accumulates in these diseases. These oligomers occur under conditions which eventually lead to the accumulation of fibrillar a ...
Voir le projet
2
Participants partenaires
TERMINÉ
Monitoring public opinion on Nanotechnology in Europe (NANOPINION)
Date du début: 1 mai 2012, Date de fin: 31 oct. 2014,
NANOPINION will provide a multi-tasking and enlivening online science-technology-social media-based platform for learning, information, outreach, dialogue and monitoring for young people, general public and consumer opinion on NT, realising the need for enhanced communication and dialogue between science and society for successful technology development and societal acceptance. A central dialogue ...
Voir le projet
20
Participants partenaires
TERMINÉ
Artificial Cells for Enzyme Replacement Therapy for Phenylketonuria (AC for PKU treatment)
Date du début: 1 mai 2012, Date de fin: 19 juin 2014,
Phenylketonuria (PKU) is the most common genetic enzyme defect, with an overall incidence in Europe and the USA of 1:10,000-20,000 live births per year. Patients suffer from a genetic defect in the liver enzyme phenylalanine hydroxylase (PAH), which normally metabolizes the amino acid phenylalanine (Phe) into the amino acid tyrosine. This specific enzyme defect, which results in an increase in the ...
Voir le projet